Combined treatment of vitamin K and teriparatide on bone metabolism and biomechanics in rats with osteoporosis

Huang,Youqing

doi:10.3892/etm.2017.5420

Combined treatment of vitamin K and teriparatide on bone metabolism and biomechanics in rats with osteoporosis

Authors:
- Youqing Huang
View Affiliations

Affiliations: Department of Pain Management, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China
Published online on: November 1, 2017 https://doi.org/10.3892/etm.2017.5420
Pages: 315-319
Copyright: © Huang . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Postmenopausal osteoporosis is a degenerative disease caused by lack of estrogen whereby bone degeneration exceeds bone formation, resulting in loss of bone mass. Various drugs have been utilized in an attempt to ameliorate bone strength in such patients. The aim of the present study was to compare the effects of vitamin K or teriparatide alone and combined on bone metabolism and biomechanics in rats with osteoporosis. The ovaries of rats were excised to construct a rat model of osteoporosis. Rats were subjected to oral intake of vitamin K or subcutaneous injection of teriparatide or both for 8 weeks. ELISA was used to detect the content of carboxylated‑type of osteocalcin (Gla‑OC) and C‑telopeptide of type I collagen (CTX‑I) in serum. Bone density of shaft of femur and metaphyseal bone was measured. Three‑point bending test was performed to analyze the load‑deformation curve of femur. Undecalcified sections of femur were stained with toluidine blue to measure bone histomorphometric static, dynamic and bone resorption parameters. Compared with monotherapy, vitamin K combined with teriparatide significantly increased serum Gla‑OC level and the number of osteoblast, decreased serum CTX‑I level, reduced the number of osteoclasts and increased bone density and strength. This study showed that the efficacy of vitamin K combined with teriparatide is better than that of monotherapy. This combined treatment can promote bone formation, inhibit bone degradation, and improve bone density and strength.

View Figures

View References

1	Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y and Shiraki M; A-TOP (Adequate Treatment of Osteoporosis) research group, : Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: The Japanese Osteoporosis Intervention Trial (JOINT) − 02. Curr Med Res Opin. 27:1273–1284. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kobayashi M, Hara K and Akiyama Y: Effects of vitamin K2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet. Bone. 35:1136–1143. 2004. View Article : Google Scholar : PubMed/NCBI
3	Tabb MM, Sun A, Zhou C, Grün F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, et al: Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem. 278:43919–43927. 2003. View Article : Google Scholar : PubMed/NCBI
4	Igarashi M, Yogiashi Y, Mihara M, Takada I, Kitagawa H and Kato S: Vitamin K induces osteoblast differentiation through pregnane X receptor-mediated transcriptional control of the Msx2 gene. Mol Cell Biol. 27:7947–7954. 2007. View Article : Google Scholar : PubMed/NCBI
5	Akiyama Y, Hara K, Kobayashi M, Tomiuga T and Nakamura T: Inhibitory effect of vitamin K2 (menatetrenone) on bone resorption in ovariectomized rats: A histomorphometric and dual energy X-ray absorptiometric study. Jpn J Pharmacol. 80:67–74. 1999. View Article : Google Scholar : PubMed/NCBI
6	Hara K, Akiyama Y, Nakamura T, Murota S and Morita I: The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone. 16:179–184. 1995. View Article : Google Scholar : PubMed/NCBI
7	Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, Sato T and Yamazaki K: Randomized controlled study on the prevention of osteoporotic fractures (OF study): A phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab. 27:66–75. 2009. View Article : Google Scholar : PubMed/NCBI
8	Flore R, Ponziani FR, Di Rienzo TA, Zocco MA, Flex A, Gerardino L, Lupascu A, Santoro L, Santoliquido A, Di Stasio E, et al: Something more to say about calcium homeostasis: The role of vitamin K2 in vascular calcification and osteoporosis. Eur Rev Med Pharmacol Sci. 17:2433–2440. 2013.PubMed/NCBI
9	Zhang K, Zhang FJ, Zhao WJ, Xing GS, Bai X and Wang Y: Effects of parathyroid hormone-related protein on osteogenic and adipogenic differentiation of human mesenchymal stem cells. Eur Rev Med Pharmacol Sci. 18:1610–1617. 2014.PubMed/NCBI
10	Rosen CJ: The role of parathyroid hormone in the management of osteoporosis. Horm Res. 64 Suppl 2:81–85. 2005.PubMed/NCBI
11	Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, et al: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344:1434–1441. 2001. View Article : Google Scholar : PubMed/NCBI
12	Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR and Nakamura T: Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone. 47:493–502. 2010. View Article : Google Scholar : PubMed/NCBI
13	Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH and Rosen CJ: Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc. 54:782–789. 2006. View Article : Google Scholar : PubMed/NCBI
14	Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D and Nakamura T: Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: A 6-month dose-response study. J Bone Miner Metab. 26:624–634. 2008. View Article : Google Scholar : PubMed/NCBI
15	Shimizu T, Takahata M, Kameda Y, Hamano H, Ito T, Kimura-Suda H, Todoh M, Tadano S and Iwasaki N: Vitamin K- dependent carboxylation of osteocalcin affects the efficacy of teriparatide (PTH(1–34)) for skeletal repair. Bone. 64:95–101. 2014. View Article : Google Scholar : PubMed/NCBI
16	Turner RT, Van der Steenhoven JJ and Bell NH: The effects of ovariectomy and 17 beta-estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res. 2:115–122. 1987. View Article : Google Scholar : PubMed/NCBI
17	Kalu DN: The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15:175–191. 1991. View Article : Google Scholar : PubMed/NCBI
18	Koshihara Y and Hoshi K: Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblast in vitro. J Bone Miner Res. 12:431 4381997. View Article : Google Scholar
19	Iwasaki Y, Yamato H, Murayama H, Takahashi T, Ezawa I, Kurokawa K and Fukagawa M: Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats. Jpn J Pharmacol. 90:88–93. 2002. View Article : Google Scholar : PubMed/NCBI
20	Hori M, Uzawa T, Morita K, Noda T, Takahashi H and Inoue J: Effect of human parathyroid hormone (PTH(1–34)) on experimental osteopenia of rats induced by ovariectomy. Bone Miner. 3:193–199. 1988.PubMed/NCBI
21	Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR and Smith SY: Daily treatment of aged ovariectomized rats with human parathyroid hormone (1–84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int. 79:262–272. 2006. View Article : Google Scholar : PubMed/NCBI
22	Iwaniec UT, Mosekilde L, Mitova-Caneva NG, Thomsen JS and Wronski TJ: Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology. 143:2515–2526. 2002. View Article : Google Scholar : PubMed/NCBI
23	Alexander JM, Bab I, Fish S, Müller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, et al: Human parathyroid hormone 1–34 reverses bone loss in ovariectomized mice. J Bone Miner Res. 16:1665–1673. 2001. View Article : Google Scholar : PubMed/NCBI
24	Matsumoto T, Miyakawa T and Yamamoto D: Effects of vitamin K on the morphometric and material properties of bone in the tibiae of growing rats. Metabolism. 61:407–414. 2012. View Article : Google Scholar : PubMed/NCBI
25	Iwamoto J, Sato Y, Takeda T and Matsumoto H: Bone quality and vitamin K2 in type 2 diabetes: Review of preclinical and clinical studies. Nutr Rev. 69:162–167. 2011. View Article : Google Scholar : PubMed/NCBI